Clinical trials: Vital Signs
Vital Sign Evaluation
Respiratory Rate Validation Study - Mindset Medical Informed Vital Core Application
Evaluating the Accuracy of a Web-Based Application - Vital Sign Measurement Platform. This single-arm cohort, open-label study is designed to evaluate the accuracy of a web-based application designed for measurements of vital…
- Trial name
- NCT06508047
- Testing
- Informed Vital Core App
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Mindset Medical
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
- Trial name
- NCT06317285
- Testing
- GSK3915393
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Arterial Disease
Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry
Clinical Investigation Plan: Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry Study ID# PR 2019-353, Version: Rev 1, Date: 15 Oct 2019 Study Dates: November 4-5, 2019
- Trial name
- NCT04285411
- Testing
- Accuracy of the VitalDetect™ pulse oximetry system
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vital USA, Inc.
Vital Sign Evaluation
A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients
Evaluating the Accuracy of a Web-Based Application - Vital Sign Measurement Platform Description This single-arm cohort, open-label, and multi-center study is designed to evaluate the accuracy of a web-based application designed…
- Trial name
- NCT05853380
- Testing
- Informed Vital Core App
- Where
- 6 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mindset Medical
Primary Systemic (AL) Amyloidosis
The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm efficacy and safety study in subjects newly diagnosed with AL amyloidosis.
- Trial name
- VITAL (NCT02312206)
- Testing
- NEOD001
- Where
- 79 sites in United States, Australia and 13 more
- Volunteers
- 260 people
- Sponsor
- Prothena Biosciences Ltd.
Pulmonary Fibrosis
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid…
- Trial name
- NCT01335464
- Testing
- BIBF 1120
- Where
- 98 sites in United States, Australia and 11 more
- Volunteers
- 515 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Respiratory Complication
Vital USA Respiratory Rate Validation In Adults
Vital USA is dedicated to developing and applying innovative electronic medical solutions that improve patient care in multiple clinical settings.
- Trial name
- RR (NCT04292639)
- Testing
- The Vital Detect Pulse Oximeter
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vital USA, Inc.
Dorsal Hands
Safety and Efficacy of Restylane Vital for Skin Rejuvenation of Dorsal Hands
The purpose of this study is to determine the safety and efficacy of using Restylane Vital for skin rejuvenation of the dorsal hands. Assessment of improvement of skin structure will be done by a blinded evaluator.
- Trial name
- NCT02545608
- Testing
- Restylane Vital
- Where
- 2 sites in China
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Coronary Artery Disease
Validation of a Vital Signs Monitoring Wristband
Today, continuous monitoring of vital signs remains a challenge since it generally requires the patient to be connected to multiple wired sensors, which restricts patient mobility in the intra-mural setting and complicates home…
- Trial name
- MULTI-VITAL (NCT05566886)
- Testing
- Continuous measurement of photoplethysmography at the wrist
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Corsano Health B.V.
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines…
- Trial name
- NCT05626751
- Testing
- HZN-825
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Vital Sign Evaluation
Clinical Validation of Non-Contact Vital Signs
Vital signs are critically important to modern emergency medical care. These metrics (heart rate (HR), respiratory rate (RR), blood pressure, temperature, and pulse oximetry) have been shown to predict a patient's morbidity…
- Trial name
- NCT07362641
- Testing
- SmartSpectra Vital Signs Monitor measurement
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Presage Technologies, Inc.
Desaturation of Blood
Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)
A clinical study designed to determine the accuracy of the peripheral capillary oxygen saturation (SpO2) function of the Vital Signs Patch (VSP) device for measuring blood saturation level.
- Trial name
- NCT01899911
- Testing
- Vital Signs Patch (VSP)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- LifeWatch Services, Inc.
Breast Cancer, Melanoma
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary…
- Trial name
- NCT01106040
- Testing
- Lymphoseek
- Where
- 8 sites in United States
- Volunteers
- 163 people
- Sponsor
- Navidea Biopharmaceuticals
Breast Cancer, Melanoma
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the…
- Trial name
- NCT00671918
- Testing
- Lymphoseek
- Where
- 15 sites in United States, Israel
- Volunteers
- 186 people
- Sponsor
- Navidea Biopharmaceuticals
Idiopathic Pulmonary Fibrosis
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment…
- Trial name
- NCT02788474
- Testing
- nintedanib
- Where
- 86 sites in United States, Australia and 11 more
- Volunteers
- 347 people
- Sponsor
- Boehringer Ingelheim
Acne Scars
An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine
The purpose of this study is to demonstrate the efficacy and safety of Restylane Vital Lidocaine when acne scars are treated
- Trial name
- NCT01807455
- Testing
- Restylane Vital Lidocaine
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Galderma R&D
Pulmonary Fibrosis
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid…
- Trial name
- NCT01335477
- Testing
- BIBF 1120
- Where
- 108 sites in United States, Canada and 15 more
- Volunteers
- 551 people
- Sponsor
- Boehringer Ingelheim
Cerebral Vasospasm
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
The objective of the study is to assess the safety and probable benefit of the Neva VS device in patients presenting with symptomatic cerebral vasospasm despite maximal medical management following aSAH.
- Trial name
- NCT03611790
- Testing
- NeVa VS
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vesalio